+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Decision making in NICE single technological appraisals: How does NICE incorporate patient perspectives?

Decision making in NICE single technological appraisals: How does NICE incorporate patient perspectives?

Health Expectations 21(1): 128-137

The National Institute for Health and Care Excellence (NICE) has an explicit mandate to include patient and public involvement in the appraisal of medicines to be available for funding on the NHS. NICE involves an appraisal committee who are required to take on board experiential evidence from patient experts alongside population-based evidence on clinical and cost-effectiveness when making a decision whether to fund a drug. This paper considers how NICE Single Technological Appraisal (STA) committees attempt to incorporate the views of patients in making decisions about funding medicines on the NHS. A prospective design was employed to follow three pharmaceutical products involving three different appraisal committees. Three data collection methods were used: analysis of documentary evidence sent by NICE, non-participant unstructured observations of the open and closed sessions of meetings and qualitative interviews. Unstructured non-participant observations were carried out at nine STA meetings, and 41 semi-structured interviews were undertaken with committee members from NICE's STA committees, patient experts, analysts from NICE's project team and drug manufacturers. Our analysis showed how the committees displayed a preference for an ideal-type of patient representative, disagreement among the committee when weighing-up patient statements in the STA process and more pre-preparation support for patient involvement. Although NICE has attempted to adopt an approach flexible to patients and carers through formal decision-making arrangements that incorporate patient views, nonetheless, the processes of the STAs can in fact undermine the very evidence collected from patient representatives.

(PDF emailed within 0-6 h: $19.90)

Accession: 059578252

Download citation: RISBibTeXText

PMID: 28686809

DOI: 10.1111/hex.12594

Related references

Seeing the NICE side of cost-effectiveness analysis: a qualitative investigation of the use of CEA in NICE technology appraisals. Health Economics 16(2): 179-193, 2006

Decision-Components of Nice's Technology Appraisals Assessment Framework. International Journal of Technology Assessment in Health Care 34(2): 163-171, 2018

A Review of Issues Affecting the Efficiency of Decision Making in the NICE Single Technology Appraisal Process. Pharmacoeconomics - Open 2019, 2019

Evidence Review Group (ERG) Critique of Systematic Reviews (SR) Submitted to Nice as Part of Single Technology Appraisals (STA) or Multiple Technology Appraisals (MTA) in the Last Three Years. Value in Health 18(7): A557, 2015

Once Nice, Always Nice? Results on Factors Influencing Nice Behavior from an Iterated Prisoners Dilemma Experiment. Behavioral Science 31(2): 327-334, 2013

Single technology appraisals by NICE: are they delivering faster guidance to the NHS?. Pharmacoeconomics 26(12): 1037-1043, 2008

Meeting of the societe de biologie de nice biological society of nice nice france may 8 1973. Comptes Rendus des Seances de la Societe de Biologie et de ses Filiales 167(6/7): 1004-1014, 1973

Assessing searches in NICE single technology appraisals: practice and checklist. International Journal of Technology Assessment in Health Care 29(3): 315-322, 2014

Cautions regarding the fitting and interpretation of survival curves: examples from NICE single technology appraisals of drugs for cancer. Pharmacoeconomics 29(10): 827-837, 2012

Should There Be an Option to Unrefer Nice Single Technology Appraisals: Case Study of Aripiprazole for Bipolar I Disorder in Adolescents. Value in Health 16(7): A615-A616, 2013

How Do Pharmaceutical Companies Model Survival of Cancer Patients? A Review of NICE Single Technology Appraisals in 2017. International Journal of Technology Assessment in Health Care 35(2): 160-167, 2019

"Yes", "No" or "Yes, but"? Multinomial modelling of NICE decision-making. Health Policy 77(3): 352-367, 2005

NICE supports shared decision making. Bmj 364: L1038, 2019

Pharmacoeconomics: NICE's approach to decision-making. British Journal of Clinical Pharmacology 70(3): 346-349, 2011

Aligned and Flexible? A Comparative Review of SMC and Nice Decision-Making. Value in Health 19(7): A347-A348, 2016